SCHEDULE 13G: BlackRock Discloses 5.5% Stake in Outset Medical

BlackRock, Inc. has reported a 5.5% beneficial ownership stake in medical technology company Outset Medical, Inc. as of June 30, 2025.

Summary

• BlackRock, Inc. has filed a Schedule 13G, disclosing its beneficial ownership in Outset Medical, Inc.
• As of June 30, 2025, BlackRock, Inc. beneficially owns 980,964 shares of Outset Medical, Inc. common stock.
• This ownership represents 5.5% of the total outstanding common stock of Outset Medical, Inc.
• BlackRock, Inc. holds sole voting power over 959,101 shares and sole dispositive power over 980,964 shares.
• The filing indicates BlackRock, Inc. is a parent holding company (HC).
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC, are identified as entities that beneficially own 5% or greater of the outstanding shares within the aggregate reported.

Sentiment

Score: 7

Explanation: The filing itself is neutral as a regulatory disclosure. However, a major institutional investor like BlackRock holding a 5.5% stake can be perceived positively by the market as a vote of confidence in the issuer, Outset Medical, Inc.

Positives

• A significant stake by a major institutional investor like BlackRock can signal confidence in Outset Medical's long-term prospects.
• BlackRock's continued beneficial ownership indicates a stable institutional presence on the shareholder register.

Negatives

• No specific negative information is disclosed in this beneficial ownership report.

Risks

• No explicit risks related to Outset Medical's operations or financial health are detailed in this beneficial ownership disclosure.

Future Outlook

The Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Outset Medical, Inc.'s future performance or BlackRock's future investment intentions beyond the scope of this regulatory filing.

Management Comments

• The filing includes a certification from BlackRock, Inc. that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant institutional investment by BlackRock, one of the world's largest asset managers, in Outset Medical, a company operating in the medical technology sector. Such an investment reflects BlackRock's portfolio allocation strategies and its view on the long-term potential of companies within the healthcare and medical device industry.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a disclosure of beneficial ownership and does not provide performance metrics for direct comparison to industry standards.
• BlackRock's 5.5% stake in Outset Medical is a notable position for a passive institutional investor, aligning with typical large-cap institutional portfolio allocations in established or growing companies within the medical technology space, similar to how large funds might hold significant, non-controlling stakes in companies like Medtronic, Intuitive Surgical, or Stryker.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by BlackRock may instill confidence among existing shareholders and potentially attract new investors, signaling institutional validation of Outset Medical.
• Investment Professionals: Provides transparency regarding a major institutional investor's position, aiding in market analysis and investment decision-making.

Next Steps

• The document does not outline specific future actions or milestones for Outset Medical, Inc. or BlackRock, Inc. beyond the regulatory requirement to update beneficial ownership disclosures if material changes occur.

Key Dates

Keywords

BlackRock, Outset Medical, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Medical Technology, Healthcare